HXK1 antibodies are immunochemical reagents designed to bind specifically to hexokinase 1, an enzyme encoded by the HK1 gene. Hexokinase 1 catalyzes the phosphorylation of glucose to glucose-6-phosphate (G6P), the first step in glycolysis, and is ubiquitously expressed across tissues, with notable roles in mitochondrial coupling, anti-apoptotic signaling, and metabolic regulation . These antibodies are pivotal for detecting HXK1 expression, localization, and interaction partners in research and diagnostics.
HXK1 antibodies are utilized in diverse experimental workflows:
Diabetic Macular Edema (DME): Anti-HXK1 autoantibodies were identified as serum biomarkers in 24.1% of DME cases, with significantly higher titers compared to controls . IgG from DME patients colocalized with HXK1 in retinal outer plexiform layers, suggesting autoimmune involvement .
Neurodegeneration: HXK1 detachment from mitochondrial membranes is linked to Parkinson’s disease (via Parkin-mediated ubiquitylation) and schizophrenia (via glutamate spillover) .
Metabolic Regulation: HXK1 couples glycolysis to mitochondrial oxidative phosphorylation by binding VDAC1, enhancing ATP production .
Anti-Apoptotic Role: HXK1 inhibits apoptosis by antagonizing Bcl-2 proteins and preventing cytochrome c release .
Validation: Antibodies like Proteintech #19662-1-AP are validated in multiple species and applications, with observed molecular weights of ~100 kDa .
Controls: Use HK1-knockout lysates (e.g., gin2-1 mutants) to confirm specificity .
Cross-Reactivity: Some antibodies (e.g., Santa Cruz sc-46695) detect mitochondrial and cytoplasmic HXK1 isoforms .
KEGG: sce:YFR053C
STRING: 4932.YFR053C